Statement by the Board of Directors of Meda

This statement is made by the Board of Directors (the ”Board”) of Meda AB (publ) (”Meda”) pursuant to the Securities Markets Act and/or the Financial Instruments Trading act.

The Board hereby confirms that it has been contacted by Mylan, Inc. (“Mylan”) regarding an indicative proposal to combine the two businesses. The Board has convened and has decided to reject the proposal. All continued discussions between Meda and Mylan have been terminated without further actions.

The Board of Directors
Meda AB (publ)

For further inquiries, please contact:

Paula Treutiger, Investor Relations                                                                                ph: +46 733-666 599                                                                                                                                                                                                                  paula.treutiger@meda.se

Meda AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 4, 2014, at 15:00 CET.

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 120 countries worldwide and the company is represented by its own organizations in over 55 countries. The Meda share is listed under
Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit
www.meda.se.

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.